Rennova Health, Inc. Announces Board of Directors

WEST PALM BEACH, FL--(Marketwired - Nov 3, 2015) - Rennova Health, Inc. (NASDAQ: RNVA) announces its board of directors boasting years of experience in executive leadership, healthcare, public policy, and financial services. Following the merger between Medytox Solutions, Inc. and CollabRx, Inc. on November 2, 2015, Rennova Health, Inc.'s board includes the following seven members: Thomas R. Mika, MBA, as executive chairman of the board; Paul R. Billings, MD, PhD, FACP, FACMG, as director; Michael L. Goldberg, managing director of Monarch Capital, LLC, as director; Robert Lee, managing partner of Sheffield Investment Partners, as director; Christopher E. Diamantis, chairman and CEO of Integrated Financial Settlements, Inc.; as director; Benjamin Frank, a retired lawyer and businessman with experience in healthcare, foreign trade, retail, business development, and government, as director; and Seamus Lagan, CEO of Rennova Health, Inc., as director.

"Every board member brings with them a wealth of practical knowledge in our field, bookended by major professional accomplishments," said Seamus Lagan, CEO of Rennova Health, Inc. "I believe their expertise will become increasingly valuable as Rennova continues to expand." 

"In my experience, this is an exceptionally strong and independent board, covering all the key areas of our business," added Thomas R. Mika. "We expect to maintain a high level of integrity in our representation of all Rennova Health stakeholders."

Thomas R. Mika, MBA, Executive Chairman of the Board
Thomas R. Mika, MBA, now holds the position of executive chairman of the board. Prior to his leadership role at CollabRx, Mika was appointed president and CEO of Tegal in 2005 and chairman of the board the following year. His previous service with Tegal was as executive vice president and CFO and as member of the board of directors from 1992 to 2002, during which he managed activities resulting in the company's 1995 Initial Public Offering. Mr. Mika holds an MBA from the Harvard Graduate School of Business.

Paul R. Billings, M.D., Ph.D., FACP, FACMG, Director
Paul R. Billings, M.D., Ph.D., FACP, FACMG, is director of the board. He is a nationally recognized expert on genomic and precision medicine and a board-certified internist and clinical geneticist. Dr. Billings has devoted his career to improving patient care by expanding the use of medically relevant genomic technologies in clinical settings, most recently as Chief Medical Officer of Life Technologies, Inc. (acquired by Thermo Fisher Scientific, Inc. in March, 2014). Dr. Billings currently serves on the Scientific Advisory Board of the FDA, the Genomic Medicine Advisory Committee at the Dept. of Veterans Affairs, and the National Academy of Sciences Institute of Medicine's Roundtable on Genomics. He holds an M.D. from Harvard Medical School and a Ph.D. in immunology from Harvard University.

Christopher E. Diamantis, Director
Christopher E. Diamantis has served since 1999 as chairman and CEO of Integrated Financial Settlements, Inc., a structured settlement consulting firm in Tallahassee, Florida. He also has been, since April 2000, director and managing partner of the Gabor Agency, Inc., a 63-year old Florida-based company specializing in investment and insurance planning for public employees and universities. Since 2007, Mr. Diamantis has been chairman of Pro Bank Financial Holding Company, the parent of Pro Bank, a community bank in Tallahassee, Florida. He also has served as director of Esquire Bank, a full-service, federally chartered savings bank in New York City, since 2011.

Benjamin Frank, Director
Benjamin Frank is a retired lawyer and businessman, with particular experience in healthcare, foreign trade, retail, business development, and government. He served from 1971 to 1987 as vice president and trustee of North Shore University Hospital, currently North Shore University Hospital, Long Island Jewish Hospital System. Mr. Frank was appointed in February 2009 by former Florida governor Charlie Crist to the board of the Health Care District of Palm Beach County, and he served as chair of the board from October 2011 to February 2013.

Michael L. Goldberg, Director
Michael L. Goldberg is the managing director of Monarch Capital, LLC, a corporate consulting company primarily servicing small to mid-sized public and private companies. Prior to his position at Monarch, he served as acting president and CEO of IDO Security, Inc., from 2006 to 2013. He has also served as a consultant to a number of private and public companies to assist in formation and capital structure. Mr. Goldberg began his career as an Asper Fellow in the U.S. Attorney's office in 1974 with the Criminal Division of the Department of Justice in Washington, D.C. (Watergate prosecution team) before becoming an assistant district attorney. He has served as a director of both private and publicly traded companies and has served on audit and compensation committees.

Seamus Lagan, Director
Seamus Lagan brings over 20 years' experience in the restructure, development, and management of startup and small companies in both the private and public sector. Mr. Lagan was the CEO of the two main subsidiaries of Medytox since 2011, whereupon he was appointed CEO of Medytox Solutions, Inc. in October 2014, and has been a key factor in both the merger of the two companies and the development of Rennova's business plan.

Robert Lee, Director
Robert Lee is the managing partner of Sheffield Investment Partners, a position he has held since 2010. From 2008 to 2010, Mr. Lee served as managing director of New Stream Capital, and from 2000 to 2007, he was managing director at CRT Capital Group. Mr. Lee is a board member of SL Investment Management. From 2001 to 2008, Mr. Lee served on the board of Springs Industries, and from 2008 until 2013, Mr. Lee served on the board of Springs Window Fashions. Mr. Lee is a former chairman of the Wake Forest School of Business, where he currently serves on the board of visitors.

About Rennova Health, Inc.
Rennova Health provides industry-leading diagnostics and supportive software solutions to healthcare providers, delivering an efficient, effective patient experience and superior clinical outcome. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare.

Safe Harbor Statement
This press release contains certain forward-looking information about Rennova Health, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "guidance", "expect", "will", "may", "anticipate", "plan", "estimate", "project", "intend", "should", "can", "likely", "could", and similar expressions are intended to identify forward looking statements. These statements include statements about our plans, strategies and prospects. Forward-looking statements are not guarantees of performance. These statements are based upon the current beliefs and expectations of our management and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot assure you that the expectations will prove to be correct. Important factors that could cause our actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. You should not place undue reliance on these forward-looking statements, which speak only as of the date such statements are made. Except to the extent required by applicable law or regulation, we undertake no obligation to update or publish revised forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.